// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Eligibility criteria requirements and adherence in advanced prostate cancer trials.

Sarah Wong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma.

Hua Chen - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

AZD-8055

Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.

Daniel Eidelberg Spratt - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Live Donor Liver Transplantation Using Grafts with More Than Two Bile Ducts – Does It Affect Patient Outcome?

D. Kollmann - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.

Sergio Faria - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Living Kidney Donor Pharmaceutical Care Needs Identified Through Linked Transplant Registry and Pharmacy Claims Data.

K. Lentine - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Angiotensin II

Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC).

Andrew Feifer - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate- risk localized prostate cancer.

Ardalan Ahmad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Long-Term Outcome of Antibody-Mediated Rejection Due to Pre-Existing vs. De Novo DSA in Kidney Allograft Recipients.

O. Aubert - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Longer Pre-Transplant Dialysis Exposure Is More Frequent in Living Donor Kidney Transplantation (LDTX) Involving Lower Income Donor and Recipients and Is Associated with an Increased Risk of LDTX Failure.

J. Gill - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.

Werner J. Struss - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

The impact of peri-operative chemotherapy for patients with lymph node-positive urothelial cancer.

Jeenan Kaiser - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.

Jason A. Efstathiou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Microarray Analysis of Rejection in Formalin-Fixed Paraffin-Embedded Biopsies: Similarities and Disparities with Conventionally Stabilized Biopsies.

K. Famulski - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer.

Ayca Gucalp - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Modular Training in Organ Procurement, in the Present Era of High BMI Donors: Validation by Results.

H. Sharma - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Molecular Classifier of Antibody-Mediated Rejection Is a Better Predictor of Histologic Rejection Than a Corresponding Transcript Set and Is Further Improved When Combined with Classifiers of Rejection Syndromes.

K. Famulski - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.

Michael Wang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

More Rapid Decline in Male VS Female Living Kidney Donations (LKD) Varies by Income.

J. Lesage - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

mRNA Biomarkers in Renal Allograft Protocol Biopsies Detected by the Nanostring Platform Predict Tolerance in Non-Human Primates.

M. Matsunami - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved